
JonesTrading analyst Debanjana Chatterjee has maintained their neutral stance on EYPT stock, giving a Hold rating on November 13. Debanjana Chatterjee’s rating is based on a balance of encouraging clinical
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EYPT | EyePoint Pharmaceuticals | 0.23 | -13.46 | -98.29% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.23 | -98.29% |

JonesTrading analyst Debanjana Chatterjee has maintained their neutral stance on EYPT stock, giving a Hold rating on November 13. Debanjana Chatterjee’s rating is based on a balance of encouraging clinical

EyePoint Pharmaceuticals ( ($EYPT) ) has shared an update. EyePoint, Inc.’s lead product candidate is DURAVYU. On November 17, 2026, a purported securities class action was filed in the U.S.

Eyepoint Pharma (($EYPT)) has held its Q3 earnings call. Read on for the main highlights of the call. EyePoint Pharma’s earnings call carried a sharply mixed message. Management acknowledged deep

Stifel lowered the firm’s price target on EyePoint (EYPT) to $5 from $6 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Reports Q3 revenue $756,000, consensus $233,080. “The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable

Eyepoint Pharma (EYPT) is scheduled to report 3rd quarter earnings on 11/12/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Eyepoint Pharma to post earnings of -$0.93

Eyepoint Pharma (EYPT) is scheduled to report 3rd quarter earnings on 11/04/2026. Regarding Q3 estimates, Wall Street analysts expect Eyepoint Pharma to post earnings of -$0.93 per share. Revenue expectations

Jones analyst Debanjana Chatterjee downgraded EyePoint (EYPT) to Hold from Buy without a price target Duravyu failed to show non-inferiority versus aflibercept in its second Phhase 3 wet age-related macular

Laidlaw downgraded EyePoint (EYPT) to Hold from Buy without a price target after the second of the two Duravyu in wet AMD Phase III studies failed to meet the primary

RBC Capital analyst Lisa Walter lowered the firm’s price target on EyePoint (EYPT) to $1 from $5 and keeps a Sector Perform rating on the shares. The LUCIA miss was
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 20, 2026 | ||||
| sell | Reiterated | Nov 19, 2026 | ||||
| hold | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| hold | Reiterated | Nov 13, 2026 | ||||
| hold | Reiterated | Nov 12, 2026 | ||||
| hold | Downgraded | Oct 20, 2026 | ||||
| buy | Reiterated | Oct 20, 2026 | ||||
| hold | Downgraded | Oct 20, 2026 | ||||
| hold | Downgraded | Oct 19, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $30.06M | $-0.69 | $304.00K | -0.16 | -0.06 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.